Clinical Trial Update: A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial comparing JNJ-70033093 (BMS-986177) with enoxaparin for thromboembolism prevention in elective total knee replacement; the study completed and res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis of Knee

Drugs mentioned

• BMS-986177 (JNJ-70033093)
• Enoxaparin (enoxaparin sodium)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Arthroplasty, Replacement, Knee | Phase 2 | Status: COMPLETED | Results posted: 2022-07-15